Advaxis, Inc., formerly Great Expectations, Inc., is a development-stage biotechnology company focused on developing cancer vaccines that utilize mechanisms of immunity. The Company uses the Listeria system licensed from the University of Pennsylvania (Penn) to secrete a protein sequence containing a tumor-specific antigen. The Company has focused its initial development efforts upon cancer vaccines targeting cervical, head and neck, breast, prostate, and other cancers. Its products in development include Lovaxin C and Lovaxin B, Lovaxin P
Currently trading at 0.126
October 1, 2009 press release: Updated Advaxis Phase I Survival Data Indicates Long-Term Immune Protection
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment